• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[儿童朗格汉斯细胞组织细胞增多症的突变与临床特征及预后的相关性]

[Correlation of Mutation with Clinical Features and Prognosis of Langerhans Cell Histiocytosis in Cildren].

作者信息

Li Xi, Xiao Li, Luo Ming-Zhu, Lei Xiao-Ying, Liu Hai-Yan, Yao Xin-Yuan, Guo Yu-Xia, Dou Ying, Yu Jie

机构信息

Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Chongqing Key Laboratory of Pediatrics, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing 400014, China.

出版信息

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Dec;32(6):1917-1922. doi: 10.19746/j.cnki.issn.1009-2137.2024.06.043.

DOI:10.19746/j.cnki.issn.1009-2137.2024.06.043
PMID:39743286
Abstract

OBJECTIVE

To explore the gene mutations of Langerhans cell histiocytosis in children, and to analyze the correlation of mutation with clinical features and prognosis of LCH, so as to provide reference for clinical diagnosis and treatment.

METHODS

Fluorescence PCR was used to detect gene mutations in paraffin-embedded tissue samples from 78 children with LCH, and the correlation of mutation with clinical characteristics and prognosis of LCH in children was analyzed.

RESULTS

Among the 78 children, 41 cases (52.6 %) had mutation, 8 cases (10.3 %) had mutation, 1 case (1.3 %) had mutation, 1 case (1.3 %) had mutation, and 1 case (1.3%) had mutation. mutation was not significantly correlated with sex, age, multisystem involvement, risk-organ involvement, CNS-risk lesions, and early treatment response in children with LCH ( >0.05), and it was also not significantly correlated with the recurrence and event-free survival (EFS) of children with LCH ( >0.05).

CONCLUSION

LCH is an inflammatory myeloid tumor. mutation is not correlated with clinical features, early treatment response, recurrence and prognosis of LCH.

摘要

目的

探讨儿童朗格汉斯细胞组织细胞增多症的基因突变情况,分析其突变与朗格汉斯细胞组织细胞增多症(LCH)临床特征及预后的相关性,为临床诊断与治疗提供参考。

方法

采用荧光PCR法检测78例LCH患儿石蜡包埋组织样本中的基因突变情况,并分析其突变与儿童LCH临床特征及预后的相关性。

结果

78例患儿中,41例(52.6%)发生 突变,8例(10.3%)发生 突变,1例(1.3%)发生 突变,1例(1.3%)发生 突变,1例(1.3%)发生 突变。 突变与LCH患儿的性别、年龄、多系统受累、危险器官受累、中枢神经系统危险病变及早期治疗反应均无显著相关性(>0.05),与LCH患儿的复发及无事件生存(EFS)也无显著相关性(>0.05)。

结论

LCH是一种炎性髓系肿瘤。 突变与LCH的临床特征、早期治疗反应、复发及预后均无相关性。

相似文献

1
[Correlation of Mutation with Clinical Features and Prognosis of Langerhans Cell Histiocytosis in Cildren].[儿童朗格汉斯细胞组织细胞增多症的突变与临床特征及预后的相关性]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Dec;32(6):1917-1922. doi: 10.19746/j.cnki.issn.1009-2137.2024.06.043.
2
[BRAF-V600E mutation and its clinical significance in children with Langerhans cell histiocytosis].[BRAF-V600E突变及其在朗格汉斯细胞组织细胞增多症患儿中的临床意义]
Zhongguo Dang Dai Er Ke Za Zhi. 2018 Apr;20(4):290-294. doi: 10.7499/j.issn.1008-8830.2018.04.007.
3
Beyond BRAF: Investigating the Clinical and Genetic Spectrum of Langerhans Cell Histiocytosis in Children.超越BRAF:探究儿童朗格汉斯细胞组织细胞增多症的临床和基因谱
Cancer Med. 2024 Dec;13(24):e70532. doi: 10.1002/cam4.70532.
4
V600E Mutation: A Significant Biomarker for Prediction of Disease Relapse in Pediatric Langerhans Cell Histiocytosis.V600E突变:小儿朗格汉斯细胞组织细胞增多症疾病复发预测的重要生物标志物。
Pediatr Dev Pathol. 2019 Oct;22(5):449-455. doi: 10.1177/1093526619847859. Epub 2019 May 9.
5
Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.95 例儿童朗格汉斯细胞组织细胞增生症的临床和预后特征:2013 年至 2020 年单中心经验。
Ann Med. 2021 Dec;53(1):1537-1546. doi: 10.1080/07853890.2021.1966085.
6
Association between clinicopathologic characteristics and BRAF expression in Chinese patients with Langerhans cell histiocytosis.中国朗格汉斯细胞组织细胞增生症患者临床病理特征与 BRAF 表达的相关性。
Thorac Cancer. 2019 Oct;10(10):1984-1992. doi: 10.1111/1759-7714.13179. Epub 2019 Aug 23.
7
Analysis of the BRAF and MAP2K1 mutations in patients with Langerhans cell histiocytosis in Japan.分析日本朗格汉斯细胞组织细胞增生症患者的 BRAF 和 MAP2K1 突变。
Int J Hematol. 2020 Oct;112(4):560-567. doi: 10.1007/s12185-020-02940-8. Epub 2020 Jul 11.
8
Genetic Landscape and Its Prognostic Impact in Children With Langerhans Cell Histiocytosis.朗格汉斯细胞组织细胞增多症患儿的基因图谱及其预后影响
Arch Pathol Lab Med. 2025 Feb 1;149(2):175-190. doi: 10.5858/arpa.2023-0236-OA.
9
Circulating cell-free BRAF as a biomarker in children with Langerhans cell histiocytosis.循环无细胞 BRAF 作为朗格汉斯细胞组织细胞增生症患儿的生物标志物。
Br J Haematol. 2017 Aug;178(3):457-467. doi: 10.1111/bjh.14695. Epub 2017 Apr 25.
10
BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.BRAF突变与高危朗格汉斯细胞组织细胞增多症相关,并与一线治疗耐药性增加有关。
J Clin Oncol. 2016 Sep 1;34(25):3023-30. doi: 10.1200/JCO.2015.65.9508. Epub 2016 Jul 5.